top of page
![[Emergency Update: Call for Caution for U.S Equities]](https://static.wixstatic.com/media/5cfcd7_908f32993d30459583a48f06216acc14~mv2.png/v1/fill/w_2056,h_1544,fp_0.50_0.50,q_95,enc_auto/5cfcd7_908f32993d30459583a48f06216acc14~mv2.png)
Jan 1211 min read
[Emergency Update: Call for Caution for U.S Equities]
Date: January 11, 2025 Overview Since the market turbulence experienced from late summer 2021 through Q4 of fiscal year 2022, U.S...
Nov 5, 20243 min read
Sinking Prospects: Cadiz, Inc. Faces Financial and Dilution Challenges
Summary: Baoro Research is initiating coverage on Cadiz, Inc. with a " Sell " recommendation, setting a target price of $2.90 per...
Oct 30, 20243 min read
Assessing the Impact of EyePoint Pharmaceutical's Recent Equity Issuance
Summary On October 28, 2024, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced an underwritten public offering of $100 million in...
Oct 24, 20245 min read
MacroGenics and TerSera: A Strategic Acquisition with Significant Risks
Summary: On October 22, 2024, MacroGenics announced an agreement with TerSera Therapeutics for the acquisition of global rights to...
bottom of page